Our team met partners and distributors from around the world to talk about licensing opportunities for our barrier-based portfolio.
Last month, Noventure took part in CPHI Milan 2026, held from 6 to 8 October. Our team, Aleix Cuenca, Ignacio Mena, Mauricio Aravena and Arieb Gani, welcomed visitors at stand 20K1, sharing Noventure’s portfolio, connecting with partners and exploring new opportunities in international markets.
Stand 20K1: Our Portfolio for Partners
Conversations at the stand centred on our clinically backed brands: the Tasectan® range for acute diarrhoea, built on mucoprotection and the barrier effect; Utipro® Plus AF for the antibiotic-free management of uncomplicated urinary tract infections; and Ulkox® for anal fissures.
Licensing That Works for Our Partners
Noventure works through a licensing model: we supply finished, ready-to-sell products together with the clinical and regulatory documentation behind them, while our partners lead local registration, launch and distribution. CPHI gave us the chance to meet current partners in person and to open new conversations with companies looking to strengthen their portfolio.
Thank You to Everyone Who Visited Stand 20K1
It was a pleasure to welcome so many of you to our booth and to exchange ideas about future collaborations. We look forward to continuing these conversations and creating new opportunities together.
